文献速递炎症性肠病

SARS-CoV-2疫苗在炎症性肠病患者中的有效性与安全性:系统评价、Meta分析与Meta回归

Effectiveness and safety of SARS-CoV-2 vaccine in Inflammatory Bowel Disease patients: a systematic review, meta-analysis and meta-regression.
PubMed 文献 · Aliment Pharmacol Ther · 2022-03-30

该系统评价与Meta分析纳入21项研究,评估SARS-CoV-2疫苗在炎症性肠病患者中的有效性与安全性。一剂与两剂接种后合并血清转化率分别为73.7%与96.8%,不同免疫抑制方案间血清转化率差异无统计学意义,疫苗类型与研究地点独立影响血清转化率,突破性感染与对照相比无统计学显著差异。作者认为SARS-CoV-2疫苗在炎症性肠病患者中安全有效。

要点

  • 炎症性肠病患者接种一剂与两剂SARS-CoV-2疫苗后合并血清转化率分别为73.7%与96.8%。
  • 不同免疫抑制方案间血清转化率差异无统计学意义。
  • 接种后突破性感染与对照相比无统计学显著差异,疫苗类型与研究地点独立影响血清转化率。

核心结论

  • 该系统评价与Meta分析提示SARS-CoV-2疫苗在炎症性肠病患者中安全有效。

研究设计与样本

  • 三位独立评价者全面检索描述炎症性肠病患者对SARS-CoV-2疫苗应答的原创文章,最终纳入21项研究进行系统评价与Meta分析,并行Meta回归。

主要发现

  • 炎症性肠病患者接种一剂与两剂SARS-CoV-2疫苗后合并血清转化率分别为73.7%与96.8%。
  • 亚组分析显示不同免疫抑制方案间血清转化率差异无统计学意义。
  • Meta回归显示疫苗类型与研究地点独立影响血清转化率。
  • 接种疫苗后炎症性肠病患者突破性感染与对照队列相比无统计学显著差异。

关键数值与推荐

  • 主要结局为炎症性肠病患者SARS-CoV-2疫苗接种后合并血清转化率、与对照队列相比的突破性COVID-19感染率以及疫苗合并不良事件率,所有结局均按一剂与两剂疫苗分别评价。
  • 采用漏斗图与Egger检验评估发表偏倚可能性。

临床怎么用

  • 原文未据此给出具体临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: There are concerns regarding the effectiveness and safety of SARS-CoV-2 vaccine in inflammatory Bowel Disease (IBD) patients. This systematic review and meta-analysis comprehensively summarises the available literature regarding the safety and effectiveness of SARS-CoV-2 vaccine in IBD. METHODS: Three independent reviewers performed a comprehensive review of all original articles describing the response of SARS-CoV-2 vaccines in patients with IBD. Primary outcomes were (1) pooled seroconversion rate SARS-CoV-2 vaccination in IBD patients (2) comparison of breakthrough COVID-19 infection rate SARS-CoV-2 vaccination in IBD patients with control cohort and (3) pooled adverse event rate of SARS-CoV-2 vaccine. All outcomes were evaluated for one and two doses of SARS-CoV-2 vaccine. Meta-regression was performed. Probability of publication bias was assessed using funnel plots and with Egger's test. RESULTS: Twenty-one studies yielded a pooled seroconversion rate of 73.7% and 96.8% in IBD patients after one and two doses of SARS-CoV-2 vaccine respectively. Sub-group analysis revealed non-statistically significant differences between different immunosuppressive regimens for seroconversion. Meta-regression revealed that the vaccine type and study location independently influenced seroconversion rates. There was no statistically significant difference in breakthrough infection in IBD patients as compared to control after vaccination. CONCLUSION: In summary, the systematic review and meta-analysis suggest that SARS-CoV-2 vaccine is safe and effective in IBD patients.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Bhurwal A, Mutneja H, Bansal V, et al. Effectiveness and safety of SARS-CoV-2 vaccine in Inflammatory Bowel Disease patients: a systematic review, meta-analysis and meta-regression. Aliment Pharmacol Ther. 2022. PMID: 35355306. doi:10.1111/apt.16913

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。